Vnitr Lek 2009, 55(4):349-353

Clinical Studies That Have Influenced the Treatment of Diabetes

J. Olšovský
Diabetologické centrum II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

In the article, the author addresses the development of the targets of diabetes treatment. He provides an overview of the key clinical studies in diabetology from which we draw knowledge and therapeutical recommendations nowadays, i.e. in the times of evidence-based medicine. The author emphasizes the need for comprehensive treatment of diabetes, i.e. the treatment of obesity, hypertension, dyslipidemia and also the impact on blood coagulation, however, focuses, in particular, on clinical studies focusing on the influence of diabetes compensation (the impact on hyperglycemia) on the development of vascular complications.

Keywords: diabetes mellitus; hyperglycemia; vascular complications; clinical studies

Received: January 30, 2009; Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Olšovský J. Clinical Studies That Have Influenced the Treatment of Diabetes. Vnitr Lek. 2009;55(4):349-353.
Download citation

References

  1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...
  2. DCCT/EDIC. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569. Go to original source... Go to PubMed...
  3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
  4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
  5. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
  6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group4. Lancet 1998; 352: 854-865.
  7. Charbonnell B, Dormandy J, Erdmann E et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5 238 patients. Diabetes Care 2004; 27: 1647-1653. Go to original source... Go to PubMed...
  8. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
  9. Kahn SE, Haffner SM, Heise MA et al. For the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherap. N Eng J Med 2006; 355: 2427-2443. Go to original source... Go to PubMed...
  10. ACCORD, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
  11. ADVANCE collaboration Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
  12. Rationale and design of the ADVANCE study. J Hypertens 2001; 19 (Suppl 4): S21-S28.
  13. ADVANCE collaboration Group ADVANCE-Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005; 22: 1-7. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.